Jump Financial LLC Buys Shares of 93,372 Viking Therapeutics, Inc. (NASDAQ:VKTX)

Jump Financial LLC purchased a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 93,372 shares of the biotechnology company's stock, valued at approximately $3,757,000. Jump Financial LLC owned approximately 0.08% of Viking Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. boosted its stake in shares of Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 309 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Viking Therapeutics in the fourth quarter valued at approximately $33,000. FIL Ltd boosted its holdings in shares of Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after buying an additional 648 shares during the period. CIBC Private Wealth Group LLC raised its holdings in Viking Therapeutics by 170.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 851 shares during the period. Finally, S.A. Mason LLC lifted its position in Viking Therapeutics by 20.0% during the 4th quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on VKTX. Piper Sandler cut their price objective on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a research report on Thursday, February 6th. Raymond James boosted their target price on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Scotiabank began coverage on shares of Viking Therapeutics in a research report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday. Finally, Maxim Group decreased their target price on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $89.75.

Insider Transactions at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan bought 1,240 shares of the business's stock in a transaction on Monday, March 31st. The shares were bought at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now owns 1,240 shares in the company, valued at approximately $29,946. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.70% of the stock is currently owned by corporate insiders.

Viking Therapeutics Trading Up 1.4 %

Shares of Viking Therapeutics stock traded up $0.32 during trading on Monday, reaching $24.26. The company's stock had a trading volume of 1,039,782 shares, compared to its average volume of 4,031,057. The stock has a 50-day moving average price of $26.94 and a two-hundred day moving average price of $41.70. The stock has a market capitalization of $2.72 billion, a P/E ratio of -24.26 and a beta of 0.84. Viking Therapeutics, Inc. has a one year low of $18.92 and a one year high of $81.86.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.05). During the same period in the prior year, the business posted ($0.25) EPS. As a group, sell-side analysts anticipate that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.